{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-281498","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.492534+00:00","generated_at":"2026-05-16T19:54:10.819903+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jade Biosciences Q3 net loss $25.2M; cash runway into H1 2028 after $135M placement","bullets":["Q3 2025 net loss of $25.2M vs $16.3M loss in Q3 2024; R&D expenses $22.0M, G&A $5.4M.","Cash, equivalents, and investments $198.9M at Sep 30; pro-forma ~$325.6M after $135M private placement closed in October.","Phase 1 trial of JADE101 (anti-APRIL for IgAN) enrolled; interim biomarker data expected H1 2026.","Unveiled JADE201 (anti-BAFF-R); first-in-human trial in rheumatoid arthritis planned for H1 2026.","Private placement of $135M extended cash runway into first half of 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-281498","json":"https://secwatch.observer/filing/0001193125-25-281498.json","markdown":"https://secwatch.observer/filing/0001193125-25-281498.md","text":"https://secwatch.observer/filing/0001193125-25-281498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525281498/0001193125-25-281498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525281498/d26766d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:54:10.819903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}